Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $4,801,302.54 in Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 433,722 shares of the company’s stock in a transaction on Monday, June 2nd. The stock was sold at an average price of $11.07, for a total value of $4,801,302.54. Following the transaction, the chief operating officer now directly owns 1,243,475 shares in the company, valued at approximately $13,765,268.25. The trade was a 25.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Eric Venker also recently made the following trade(s):

• On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The shares were sold at an average price of $11.22, for a total value of $6,353,639.16.
• On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00.
• On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.22, for a total value of $1,022,000.00.
• On Monday, March 24th, Eric Venker sold 434,478 shares of Roivant Sciences stock. The stock was sold at an average price of $10.82, for a total transaction of $4,701,051.96.
• On Thursday, March 20th, Eric Venker sold 315,522 shares of Roivant Sciences stock. The shares were sold at an average price of $11.06, for a total transaction of $3,489,673.32.

Roivant Sciences Stock Down 0.3%

Shares of ROIV stock opened at $11.21 on Thursday. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06. The stock has a market capitalization of $8.00 billion, a PE ratio of -74.73 and a beta of 1.23. The firm has a 50 day moving average of $10.59 and a two-hundred day moving average of $11.02.

Roivant Sciences (NASDAQ:ROIV) last issued its quarterly earnings results on Thursday, May 29th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The business had revenue of $7.57 million during the quarter, compared to analysts’ expectations of $62.17 million. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. During the same period in the prior year, the business earned ($0.23) EPS. Analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Institutional Investors Weigh In On Roivant Sciences

Several institutional investors have recently modified their holdings of ROIV. Barclays PLC lifted its position in Roivant Sciences by 19.7% in the third quarter. Barclays PLC now owns 459,521 shares of the company’s stock valued at $5,302,000 after acquiring an additional 75,609 shares during the last quarter. Elevate Capital Advisors LLC purchased a new stake in Roivant Sciences in the fourth quarter valued at $2,116,000. Thompson Siegel & Walmsley LLC lifted its position in Roivant Sciences by 10.1% in the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company’s stock valued at $6,688,000 after acquiring an additional 51,705 shares during the last quarter. Russell Investments Group Ltd. lifted its position in Roivant Sciences by 478.6% in the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company’s stock valued at $28,000 after acquiring an additional 1,948 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Roivant Sciences in the fourth quarter valued at $995,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ROIV shares. Cantor Fitzgerald raised shares of Roivant Sciences to a “strong-buy” rating in a research note on Tuesday, March 4th. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Wednesday, May 28th.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.